Production , purification and preparation of various candidiate vaccines

各种候选疫苗的生产、纯化和制备

• 批准号: 8741643
• 负责人: Joseph Shiloach
• 金额: $ 28.59万
• 依托单位: NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8741643
• 关键词: Bacillus anthracis; Bioreactors; Biotechnology; Bioterrorism; Cell Culture Techniques; Cells; Chimeric Proteins; Collaborations; Conjugate Vaccines; Development; E coli polysaccharide K1; Haemophilus influenzae; Influenza; Laboratories; MDCK cell; Malaria; Methods; National Institute of Allergy and Infectious Disease; National Institute of Child Health and Human Development; Pertussis; Preparation; Production; Proteins; Public Health; Respiratory syncytial virus; Rotavirus; Rotavirus Vaccines; Scientist; Shigella; Shigella flexneri; Structure; Suspension substance; Suspensions; Vaccines; Viral Vaccines; Work; improved; influenza virus vaccine; research study; transmission process

The Biotechnology Lab is wrapping its collaboration work with the NICHD and NIAID on the development of new conjugated vaccines against Shigella flexneri, Shigella Sonnie, Bortedella pertussis Haemophilus influenzae type A, Bortedella pertussis, and protein vaccines for Bacillus anthracis and Malaria transmission blocking vaccine. Working together with scientists from the FDA, the laboratory is evaluating the potential production of influenza virus vaccine form the newly developed MDCK cells, and on the structure of the polysaccharide from E. coli K1 and Meningococcal C. The Biotechnology Lab continued to work on the development of new production approaches for viral vaccines by using suspension cell culture, concentrating on influenza and rotavirus. In addition we are working on expressing the respiratory syncytial Virus (RSV) fusion protein from HEK cells growing in suspension in bioreactor. The proper constructs are being made and preliminary experiments on expression and purifications are being conducted.

生物技术实验室正在完成与NICHD和NIAID的合作工作，开发针对福氏志贺菌、Sonnie志贺菌、百日咳杆菌、A型流感嗜血杆菌、百日咳杆菌的新型结合疫苗，以及炭疽杆菌蛋白疫苗和疟疾传播阻断疫苗。 该实验室与FDA的科学家合作，正在评估新开发的MDCK细胞生产流感病毒疫苗的可能性，以及E. coliK1和脑膜炎球菌C.生物技术实验室继续致力于通过使用悬浮细胞培养开发新的病毒疫苗生产方法，重点是流感和轮状病毒。此外，我们正在研究从生物反应器中悬浮生长的HEK细胞表达呼吸道合胞病毒（RSV）融合蛋白。目前正在进行适当的构建，并进行表达和纯化的初步实验。